Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (16)

2023

  1. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

2022

  1. Gadolinium-enhanced brain lesions in multiple sclerosis relapse

    Neurologia, Vol. 37, Núm. 7, pp. 557-563

  2. Recommendations for the diagnosis and treatment of multiple sclerosis relapses

    Journal of Personalized Medicine, Vol. 12, Núm. 1

  3. Seroprevalence of SARS‐CoV‐2 in a Cohort of Patients with Multiple Sclerosis under Disease‐Modifying Therapies

    Journal of Clinical Medicine, Vol. 11, Núm. 9

2021

  1. Assessing blood-based biomarkers to define a therapeutic window for natalizumab

    Journal of Personalized Medicine, Vol. 11, Núm. 12

  2. Direct costs of relapses in patients with relapsing-remitting multiple sclerosis

    Neurology Perspectives, Vol. 1, Núm. 3, pp. 160-169

2019

  1. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial

    European Journal of Neurology, Vol. 26, Núm. 3, pp. 525-532

  2. Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment

    Mediators of Inflammation, Vol. 2019

2018

  1. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

    Multiple Sclerosis Journal, Vol. 24, Núm. 14, pp. 1843-1851

  2. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

    CNS Neuroscience and Therapeutics, Vol. 24, Núm. 12, pp. 1175-1184

2016

  1. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses

    Multiple Sclerosis, Vol. 22, Núm. 1, pp. 117-121

2015

  1. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses

    Multiple Sclerosis Journal, Vol. 21, Núm. 5, pp. 646-650

2014

  1. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

    Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 717-725

2010

  1. Multiple sclerosis epidemiological situation update: Pertinence and set-up of a population based registry of new cases in Catalonia

    Revista de Neurologia, Vol. 50, Núm. 10, pp. 623-633

2004

  1. IFN-β treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remiting multiple sclerosis

    Multiple Sclerosis, Vol. 10, Núm. 6, pp. 630-635

2002

  1. Treatment with methylprednisolone in relapses of multiple sclerosis patients: Immunological evidence of immediate and short-term but not long-lasting effects

    Clinical and Experimental Immunology, Vol. 127, Núm. 1, pp. 165-171